(1 - 11 von 24
)
Iain Dukes - Bottin des Personnalités - CFNEWSwww.cfnews.net › ... › Bottin des Personnalités
www.cfnews.net
Toutes les infos sur Iain Dukes - Bottin des Personnalités avec Corporate Finance News (cfnews) : historique, secteurs d'activité et informations ...
Angiex further bolsters its Executive Teamangiex.com › news › angiex-further-bolsters-its-exe...
angiex.com
I am driven to translate that into a meaningful benefit for cancer patients,” said Dr. Sager. Iain Dukes, executive chairman of Angiex and venture partner of ...
Event - Biocom Californiabiocom.org › Events
biocom.org
Iain Dukes, M.A., D.Phil., SVP, Business Development & Licensing. Alan Fuhrman, Former CFO, Ambit Bioscience. Tadashi Funahashi, MD Chief Innovation Officer ...
BioMarin, Merck, and Sanofi: The biggest news so far from 'JPM15' and...
www.biopharmadive.com
BioPharma
Snap Bio and i2020 Accelerator (Torrey Pines Investment)www.i2020accelerator.com › ...
www.i2020accelerator.com
In connection with the financing, Carl Gordon and Iain Dukes from OrbiMed, Nikolay Savchuk from Torrey Pines Investment and Augustine Lawlor from Health ...
News from the Chestnut Hill Conservancychestnuthillpa.com › News
chestnuthillpa.com
Kim and Iain Dukes. Joseph Kotarski, Jr. and Federico Mingozzi. Betsy and Robert Lukens. Pascal Maeter. Judith and Clay von Seldeneck.
ENYO Pharma completes €40M Series B | PitchBookpitchbook.com › newsletter
pitchbook.com
· The company will use the proceeds to fund Phase II trials. OrbiMed venture partner Iain Dukes will join ENYO's...
Greed is misunderstood? Tackling biopharma's pricing image problem |...
www.biopharmadive.com
BioPharma
Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination...
www.merck.com
· the potential of MK for the treatment of cancer,” said Iain Dukes, senior vice president, Licensing and External Scientific Affairs, ...
Merck & Co licences late-stage psoriasis drug to Sun - PharmaTimes
www.pharmatimes.com
Merck & Co has decided not to carry on paying for the development of its late-stage psoriasis drug tildrakizumab, choosing instead to license the treatment to...
Viriom Announces New CEO Appointmentwww.viriom.com › news › viriom-announces-new-c...
www.viriom.com
· Viriom Inc. is pleased to announce the appointment of Iain Dukes, M.A., D.Phil., as its new CEO. Dr. Dukes brings to Viriom over 20 years of ...
sortiert nach Relevanz / Datum